Thierry Laugel, PhD

Managing partner, Kurma Life Sciences Partners – Board member

Thierry Laugel is the managing partner of Kurma Life Science Partners. Thierry holds a PhD in pharmacology and an MBA from INSEAD.

After his dissertation, Thierry was a scientific representative for Laboratoires Fournier in Japan for four years at a time when Lipanthyl was released in Japan and research programmes were being rolled out with Grelan, a Takeda Group company.

He subsequently joined Flamel Technologies after its IPO on Nasdaq, as project director for Pharmaceutical R&D. In 1998, he moved to the investment world, firstly at CDC Innovation and then with AGF Private Equity, where he supervised the healthcare investment team.

He subsequently co-founded Kurma Life Sciences in 2008.

the Management team

Joël Crouzet, PhD

CEO & Chairman

Annegret Van der Aa, PhD

CSO & CDO

Stéphane Durant des Aulnois, MSc

CFO

Gerhard Müller, PhD

Head of Medicinal Chemistry

Hélène Asnagli, PhD

Head of Biology & Pharmacology

Scientific Founder

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors

David Main, BSc, MBA

President and CEO, Notch Therapeutics - Independent Board member

Joël Crouzet, PhD

CEO & Chairman

Pascal Neuville, PhD

CEO, Domain Therapeutics - Board member

Laurent Audoly, PhD

Founder & CEO of Parthenon Therapeutics - Board member

Thierry Laugel, PhD

Managing partner, Kurma Life Sciences Partners - Board member

Hadrien Bouchez

Principal, Kurma Life Sciences Partners - Board member

Aidan King, MBA, CFA

Managing Partner & Co-Founder, Fountain Healthcare Partners - Board member

Tania Papkovskaia, PhD

Senior Associate, Fountain Healthcare Partners - Board observer

Scientific and Clinical Advisors

Piet Wigerinck, PhD

Chairman of the Scientific Advisory Board

Prof. Vibeke Strand

Stanford Univ, School of Med (US) | Rheumatology-SLE

Prof. Michelle Petri

John Hopkins Medicine (US) | Rheumatology-SLE

Prof. Ronald van Vollenhoven

UMC Amsterdam (NL) | Rheumatology-SLE

Jean-Philippe Herbeuval, PhD

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Martine Smit, PhD

Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam

Graeme Milligan, PhD

Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow

Michel Bouvier, PhD

Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal